WHO ICTRP trial

A Study of the Effect of IW-1701, a Stimulator of Soluble Guanylate Cyclase…

EUCTR2019-001899-11-GB · EU Clinical Trials Register · Not Recruiting

Key facts

Trial ID EUCTR2019-001899-11-GB
Public title A Study of the Effect of IW-1701, a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
Scientific title A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease - Strong SCD
Primary sponsor Cyclerion Therapeutics, Inc.
Registry EU Clinical Trials Register
Recruitment status Not Recruiting
Study type Interventional clinical trial of medicinal product
Phase Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries United States;Lebanon;United Kingdom
Conditions Stable Sickle Cell Disease (SCD) MedDRA version: 21.0 Level: PT Classification code 10040644 Term: Sickle cell disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Blood and…
Interventions Product Name: Olinciguat Product Code: IW-1701 Pharmaceutical Form: Tablet INN or Proposed INN: Olinciguat CAS Number: 1628732-62-6 Current Sponsor code: IW-1701 Other descriptive name: MM-464110 (alternate Cyclerion code); PCI-103303 (PCI…
Registration date Aug 29, 2019
Target size 88
Secondary IDs C1701-202;NCT03285178
Registry page clinicaltrialsregister.eu

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations